Mixed amfetamine salts

Mixed amfetamine salts Reactions 1680, p233 - 2 Dec 2017 Psychosis: case report A 55-year-old man developed psychosis during treatment with mixed amfetamine salts [Adderall; route, dosage and duration of treatment to reaction onset not stated]. The man had an year history of bizarre delusions and visual hallucinations. He had been attacked by gamma rays by airplanes, which infected his blood with radiation. The delusions worsened by the recent life stressors. He had a history of attention deficit hyperactivity disorder, for which he was receiving prescribed mixed amfetamine salts, since the last six years. He reported that he took mixed amfetamine salts more than the prescribed dose. He had multiple hospitalisations due to delusions in the past year. An examination revealed that he was obese with anxious mood, with a goal-directed thought-process, poor insight and poor judgement. A diagnosis of mixed amfetamine salts induced psychosis was made. The man’s mixed amfetamine salts treatment was discontinued. He was monitored closely for withdrawal symptoms. Within a week of mixed amfetamine salts discontinuation, his condition improved and he was subsequently discharged. No psychosis was reported in the follow-up visits. Author comment: "Chronic and high-dose consumption of [mixed amfetamine salts] can cause psychosis, presented as delusions, hallucinations, agitation, and anxiety resembling schizophrenia." Harrigan M, et al. A case report of Adderall-induced bizarre delusions. CNS Spectrums 22: 85-86 abstr. 142, No. 1, Feb 2017. Available from: URL: http:// doi.org/10.1017/S1092852916000900 [abstract] - USA 803284810 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Mixed amfetamine salts

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial